Why is Alembic Pharmaceuticals Ltd. falling/rising?

Recent Price Movement and Market Performance

The stock has underperformed both its sector and benchmark indices consistently. Over the last week, Alembic Pharmaceuticals has fallen by 4.64%, significantly lagging behind the Sensex’s 2.55% decline. This underperformance extends to the one-month period, where the stock dropped 9.68% compared to the Sensex’s modest 1.29% fall. Year-to-date, the stock has declined by 5.60%, again underperforming the broader market’s 1.93% decrease. Such persistent weakness is compounded by the fact that the stock has been trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish technical outlook.

Investor participation has increased, with delivery volumes on 08 Jan rising by 62.49% compared to the five-day average, suggesting heightened trading activity amid the price decline. Despite this, liquidity remains adequate for moderate trade sizes, but the prevailing sentiment appears cautious.

Fundamental Strengths Amidst Weak Price Action

Despite the recent price weakness, Alembic Pharmaceuticals exhibits some positive fundamental attributes. The company maintains a strong ability to service its debt, with a low Debt to EBITDA ratio of 0.90 times, reflecting prudent financial management. Its latest quarterly results, reported in September 2025, showed operating profit to interest coverage at a robust 13.03 times, with PBDIT reaching a high of ₹315.69 crores and profit before tax excluding other income at ₹216.81 crores. These figures underscore operational efficiency and profitability at the quarter level.

Additionally, the company’s return on capital employed (ROCE) stands at a respectable 12.6%, and it trades at an attractive valuation with an enterprise value to capital employed ratio of 2.6. This suggests that Alembic Pharmaceuticals is valued at a discount relative to its peers’ historical averages, potentially offering value for long-term investors. Institutional holdings are also relatively high at 20.34%, indicating confidence from sophisticated investors who typically conduct thorough fundamental analysis.

Challenges Weighing on the Stock

However, these positives are overshadowed by significant concerns regarding the company’s growth trajectory and market performance. Over the past five years, operating profit has declined at an annualised rate of 8.80%, signalling poor long-term growth. This sluggish expansion is reflected in the stock’s returns, which have been disappointing across multiple time horizons. The stock has generated a negative return of 24.42% over the last year, starkly contrasting with the Sensex’s positive 7.67% gain during the same period. Even over three years, while the stock has posted a cumulative gain of 42.97%, it still marginally trails the Sensex’s 37.58% rise, and over five years, the stock’s performance is notably weak with a 26.77% decline compared to the Sensex’s 71.32% surge.

Moreover, the stock has underperformed the BSE500 index consistently over the last three years, one year, and three months, reinforcing the narrative of below-par performance. The slight 0.2% fall in profits over the past year further dampens investor enthusiasm, suggesting that the company is struggling to translate operational efficiency into meaningful profit growth.

Conclusion: Why Alembic Pharmaceuticals Is Falling

The decline in Alembic Pharmaceuticals’ share price as of 09-Jan is primarily driven by its sustained underperformance relative to market benchmarks and peers, coupled with disappointing long-term growth metrics. While the company demonstrates solid debt management and operational profitability at the quarterly level, these strengths have not been sufficient to offset investor concerns about its declining operating profits and lacklustre returns over the past year and beyond. The stock’s position below all major moving averages and its consecutive five-day fall further reinforce the bearish sentiment prevailing among investors.

In summary, despite some attractive valuation metrics and institutional backing, Alembic Pharmaceuticals faces challenges in delivering consistent growth and outperforming the broader market, which has led to its recent price decline. Investors are likely weighing these factors carefully, resulting in subdued demand and a cautious outlook for the stock in the near term.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →